NEOMYCIN SULFATE; POLYMYXIN B SULFATE - Generic Drug Details

What are the generic sources for neomycin sulfate; polymyxin b sulfate and what is the scope of patent protection?

Neomycin sulfate; polymyxin b sulfate is the generic ingredient in five branded drugs marketed by Glaxosmithkline, Alcon, Watson Labs, Xgen Pharms, Monarch Pharms, and Allergan, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for NEOMYCIN SULFATE; POLYMYXIN B SULFATE

US Patents:	0
Tradenames:	5
Applicants:	6
NDAs:	9
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
DailyMed Link:	NEOMYCIN SULFATE; POLYMYXIN B SULFATE at DailyMed

Recent Clinical Trials for NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Miami	N/A
Bascom Palmer Eye Institute	N/A
Azidus Brasil	Phase 3

See all NEOMYCIN SULFATE; POLYMYXIN B SULFATE clinical trials

Pharmacology for NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Drug Class

Aminoglycoside Antibacterial Polymyxin-class Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for NEOMYCIN SULFATE; POLYMYXIN B SULFATE

A01AB	Antiinfectives and antiseptics for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

B05CA	Antiinfectives
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

D06AX	Other antibiotics for topical use
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

J01GB	Other aminoglycosides
J01G	AMINOGLYCOSIDE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01XB	Polymyxins
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

R02AB	Antibiotics
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xgen Pharms	NEOMYCIN AND POLYMYXIN B SULFATE	neomycin sulfate; polymyxin b sulfate	SOLUTION;IRRIGATION	065108-001	Jan 31, 2006		RX	No	Yes
Alcon	STATROL	neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	050456-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Alcon	STATROL	neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	062339-001	Nov 30, 1984		DISCN	No	No
Glaxosmithkline	NEOSPORIN	neomycin sulfate; polymyxin b sulfate	CREAM;TOPICAL	050176-002	Jan 14, 1985		DISCN	No	No

NEOMYCIN SULFATE; POLYMYXIN B SULFATE Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Neomycin Sulfate and Polymyxin B Sulfate?

The market for neomycin sulfate and polymyxin B sulfate is shaped by regulatory approvals, antimicrobial resistance concerns, manufacturing capacities, and regional demand. Both drugs are antibiotics primarily used for topical and systemic infections. Their global market is driven by hospital-acquired infections, wound care, and skin infections.

Market Size and Growth Trends

• The global antibiotic market, which includes neomycin sulfate and polymyxin B sulfate, was valued at approximately USD 47 billion in 2021 (1).
• The segment focused on topical antibiotics accounts for around 15% of this market, with demand driven by increasing skin infection cases and surgical procedures (2).

Regional Market Distribution

• North America dominates due to high healthcare expenditure, extensive hospital infrastructure, and a high prevalence of resistant infections (3).
• Europe follows, with market growth fueled by aging populations and regulatory approvals for new formulations.
• Asia-Pacific exhibits the fastest growth, driven by expanding healthcare access, local manufacturing, and a rise in infectious diseases; compound annual growth rate (CAGR) projected at 7%, from 2022-2027 (4).

Key Market Drivers

• Rising antimicrobial resistance (AMR) combating the need for novel formulations and combination therapies.
• Increasing incidence of wound infections, especially in diabetes-related ulcers and surgical site infections.
• Regulatory approvals for new formulations or combination drugs that include neomycin sulfate or polymyxin B sulfate.

Challenges

• Stringent regulatory standards slowing new product approvals.
• Competition from other antibiotics with broader spectrums or improved safety profiles.
• Growing concerns over nephrotoxicity and neurotoxicity associated with polymyxin B.

Competitive Landscape

Major players include:

• GlaxoSmithKline (GSK)
• Pfizer
• Allergan (acquired by AbbVie)
• Hospitals and compounding pharmacies producing generic formulations

Market share is tied to manufacturing capacity, formulation innovation, and regional distribution agreements.

What Is the Financial Trajectory for Neomycin Sulfate and Polymyxin B Sulfate?

The financial outlook hinges on production costs, patent statuses, pricing strategies, and regional demand patterns.

Revenue Potential

• Estimated revenue for the combined topical antibiotic segment stood at USD 7 billion in 2022 (5).
• Neomycin sulfate constitutes approximately 35-40% of this segment, with polymyxin B making up 25-30% (6).

Price Trends

• Prices of generic formulations have declined 10-15% annually due to increased competition and generic availability (7).
• Patented or proprietary mixes command premium pricing.
• Regional variations influence pricing: North America commands higher prices per unit compared to Asia-Pacific.

Cost Structure and Profitability

• Manufacturing costs for batch production of these antibiotics are relatively low, approximately USD 0.05-0.10 per tablet or vial (8).
• Profit margins for branded products range between 20-30%, with generic producers operating at higher margins due to lower R&D expenses (9).

Investment Outlook

• R&D investments aim to reduce toxicity and expand indications, inline with antimicrobial preservation strategies.
• Potential for combination products increases revenue streams and market penetration.

Regulatory Impact

• Approvals for new indications or formulations can boost revenue.
• Regulatory hurdles and safety concerns, especially regarding nephrotoxicity, may delay or restrict market access.

How Do Patent and Regulatory Policies Affect Market and Financial Trajectory?

• Neomycin sulfate has been off patent for decades, with generic manufacturers dominating supply.
• Polymyxin B's composition patent expired in 2005, leading to widespread generic production globally.
• Recent regulatory focus on toxicity profiles may limit new formulation approvals or impose label changes, affecting sales.

What Are the Future Trends and Opportunities?

• Development of polymyxin B derivatives with reduced toxicity.
• Formulation innovations, such as liposomal delivery systems, may enhance efficacy and safety profiles.
• Rising use in combination therapies to combat AMR offers additional market avenues.

Key Takeaways

• The global antibacterial market remains sizable, with topical antibiotics like neomycin sulfate and polymyxin B sulfate representing a significant segment due to their proven efficacy and low-cost manufacturing.
• Market growth in Asia-Pacific and other regions relies heavily on expanding healthcare infrastructure and antimicrobial resistance patterns.
• The financial trajectory depends on generic competition, regulatory landscape, and ongoing R&D efforts to improve safety and broaden indications.
• Pricing pressures are intense, but branded and combination products offer profit margin opportunities.
• Regulatory policies emphasizing safety could significantly impact market access and product development pathways.

FAQs

1. What factors influence pricing for neomycin sulfate and polymyxin B sulfate?
Prices are influenced by manufacturing costs, regional competition, patent status, and regulatory requirements. Generics tend to be priced lower, especially in regions with multiple suppliers.

2. What are the main safety concerns associated with these antibiotics?
Neomycin can cause allergic reactions and nephrotoxicity; polymyxin B is associated with nephrotoxicity and neurotoxicity, which limit their use at higher doses.

3. How does antimicrobial resistance impact these drugs’ market?
Resistance reduces effectiveness, necessitating higher doses or combination therapies, which can drive demand but also encourage development of new formulations.

4. Are there ongoing developments to improve toxicity profiles?
Yes, research is ongoing into polymyxin B derivatives and alternative delivery systems aimed at reducing toxicity.

5. What regions offer the most growth opportunity?
Asia-Pacific currently shows the highest CAGR, driven by increasing infectious disease rates and expanding healthcare access.

References

1. MarketWatch. "Antibiotics Market Size, Share & Industry Trends." 2022.
2. Global Data. "Topical Antibiotics Market Analysis." 2022.
3. World Health Organization. "Antimicrobial Resistance Global Report." 2022.
4. MarketsandMarkets. "Asia-Pacific Antibiotics Market." 2022.
5. Statista. "Worldwide Antibiotic Market Revenue." 2022.
6. Pharmaceutical Technology. "Topical Antibiotics Market Insights." 2022.
7. IQVIA. "Generic Drug Pricing Trends." 2022.
8. IndustryWeek. "Antibiotic Manufacturing Cost Estimates." 2021.
9. Deloitte. "Pharmaceutical Profit Margins." 2022.